Minerva Neurosciences, a clinical stage biotech developing treatments for CNS diseases, filed on Wednesday with the SEC to raise up to $69 million in an initial public offering. The company has four candidates designed to treat schizophrenia, major depressive disorder, insomnia and Parkinson's disease. The Cambridge, MA-based company, which was founded in 2007, plans to list on the NASDAQ under the symbol NERV. Minerva Neurosciences initially filed confidentially on February 14, 2014. Jefferies is the sole bookrunner on the deal. No pricing terms were disclosed.
